Author:
Badtke Melanie M.,Jambal Purevsuren,Dye Wendy W.,Spillman Monique A.,Post Miriam D.,Horwitz Kathryn B.,Jacobsen Britta M.
Publisher
Springer Science and Business Media LLC
Reference56 articles.
1. Ravdin PM, Burris HA III, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E, Bellet RE (1995) Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13(12):2879–2885
2. Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel RG, Ravdin PM, Holmes FA, Rahman Z, Schottstaedt MW, Erban JK, Esparza-Guerra L, Earhart RH, Hortobagyi GN, Burris HA 3rd (1998) A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 16(10):3362–3368
3. Sawaki M, Ito Y, Hashimoto D, Mizunuma N, Takahashi S, Horikoshi N, Tada K, Kasumi F, Akiyama F, Sakamoto G, Imai T, Nakao A, Hatake K (2004) Paclitaxel administered weekly in patients with docetaxel-resistant metastatic breast cancer: a single-center study. Tumori 90(1):36–39
4. McGrogan BT, Gilmartin B, Carney DN, McCann A (2008) Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 1785(2):96–132. doi: 1016/j.bbcan.2007.10.004
5. Villeneuve DJ, Hembruff SL, Veitch Z, Cecchetto M, Dew WA, Parissenti AM (2006) cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. Breast Cancer Res Treat 96(1):17–39
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献